Skip to main content
OpenTrials
Completed

NCT Number: NCT03291782

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

This initial clinical study in the US will be a randomized, double-blind, placebo-controlled, single-dose, dose-escalation, and sequential cohort study to evaluate the safety, tolerability, PK and PD of D-0120-NA in fasting, healthy volunteers (HVs).

In food effect cohort, subjects will each receive 2 doses of D-0120-NA in an open-label manner; once in the fasted state and once in the fed state.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Covance Daytona Beach Clinical Research Unit

Daytona Beach, Florida, 32117, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must be medically documented as healthy and acceptable at physical examination.
  • Subjects serum uric acid level at screening ≥ 4.5 mg/dL.
  • Subjects must have a BMI between 18.0 and 30.0 kg/m2 and a body weight of 50 kg or higher
  • Subjects must have all laboratory parameters within the normal range or considered not clinically significant by the principal investigator.
  • Subjects must have a normal urinalysis, eGFR, ECG or results considered not clinically significant by the principal investigator.
  • Subjects are able to understand the study procedures and risks involved and must provide signed informed consent to participate in the study.

Exclusion criteria

  • Any history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders.
  • Any history or suspicion of kidney stones.
  • Positive for HIV, Hepatitis B, and/or Hepatitis C.
  • Subjects who have used prescription drugs, over-the-counter drugs, or herbal remedies within 14 days before Day 1 of study medication dosing.
  • Undergone major surgery within 3 months prior to Day 1.
  • Women who are pregnant or breastfeeding.
  • Subjects who received any investigational test article within 5 half-lives or 30 days prior to Day 1 study medication dosing.
  • Subjects who consumed Seville oranges- or grapefruit-containing foods or beverages within 7 days before Day 1 and during the entire study duration.
  • Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study.

Treatment and study plan

D-0120

Drug

oral, single dose

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: 2 weeks

    Adverse Events and changes of Laboratory, Electrocardiogram, and Vital Signs

Secondary outcomes

  1. Pharmacokinetic: area under the plasma concentration versus time curve (AUC)

    Time frame: Day-1 through 3

    AUC: area under the plasma concentration versus time curve for D-0120

  2. Pharmacokinetic: maximum plasma drug concentration (Cmax)

    Time frame: Day-1 through 3

    Cmax: maximum plasma drug concentration of D-0120

  3. Pharmacokinetic: Time to reach the Cmax (Tmax)

    Time frame: Day-1 through 3

    Tmax: Time to reach the Cmax of D-0120

  4. Pharmacokinetic: Apparent terminal half-life (t1/2)

    Time frame: Day-1 through 3

    t1/2: apparent terminal half-life of D-0120

  5. Pharmacokinetic: Apparent oral clearance (CL/F)

    Time frame: Day-1 through 3

    CL/F: Apparent oral clearance of D-0120

  6. Pharmacokinetic: Apparent volume of distribution (Vz/F)

    Time frame: Day-1 through 3

    Vz/F: Apparent volume of distribution of D-0120

  7. PD profile of D-0120 from plasma and urine

    Time frame: Day-1 through 3

    Profile in terms of Serum uric acid and creatinine; Urine uric acid and creatinine. These parameters will be combined to report fractional excretion of uric acid (FEUa %)

Sponsors and collaborators

Lead sponsor

InventisBio Co., Ltd

Industry

Registry information

Official study title

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, and Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics; Including an Open-label Cohort to Determine the Effect of Food on the Pharmacokinetics of D-0120-NA Tablet in Healthy Volunteers in the United States

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Sep 25, 2017
Registry last updated
Dec 19, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.